Discordance between the results and conclusions of ICON7 - Authors' reply

Amit M. Oza; Adrian D. Cook; Richard Kaplan; Mahesh K.B. Parmar; Timothy J. Perren

doi:10.1016/S1470-2045(15)00311-3

Discordance between the results and conclusions of ICON7 - Authors' reply

Amit M. Oza
, Adrian D. Cook
, Richard Kaplan
, Mahesh K.B. Parmar
, Timothy J. Perren

Research output: Contribution to journal › Letter › peer-review

2 Scopus citations

Original language	English
Pages (from-to)	e478-e479
Journal	The Lancet Oncology
Volume	16
Issue number	13
DOIs	https://doi.org/10.1016/S1470-2045(15)00311-3
State	Published - 2015
Externally published	Yes

Access to Document

10.1016/S1470-2045(15)00311-3

Cite this

@article{d68aa620225c4a39be62ab62d04bffaf,

title = "Discordance between the results and conclusions of ICON7 - Authors' reply",

author = "Oza, \{Amit M.\} and Cook, \{Adrian D.\} and Richard Kaplan and Parmar, \{Mahesh K.B.\} and Perren, \{Timothy J.\}",

note = "Funding Information: TJP has received personal fees from Roche during the conduct of the study. RK, MKBP, and TJP have received grant funding from Roche during the study period. MKBP and TJP have received non-financial support from Roche during the study period. TJP has received personal fees from Novartis and AstraZeneca outside the submitted work, and has received other fees from several other pharmaceutical companies and research organisations in connection with the costs of running a broad research portfolio, outside the submitted work. ADC and AMO declare no competing interests.",

year = "2015",

doi = "10.1016/S1470-2045(15)00311-3",

language = "English",

volume = "16",

pages = "e478--e479",

journal = "The Lancet Oncology",

issn = "1470-2045",

publisher = "Elsevier Ltd.",

number = "13",

}

TY - JOUR

T1 - Discordance between the results and conclusions of ICON7 - Authors' reply

AU - Oza, Amit M.

AU - Cook, Adrian D.

AU - Kaplan, Richard

AU - Parmar, Mahesh K.B.

AU - Perren, Timothy J.

N1 - Funding Information: TJP has received personal fees from Roche during the conduct of the study. RK, MKBP, and TJP have received grant funding from Roche during the study period. MKBP and TJP have received non-financial support from Roche during the study period. TJP has received personal fees from Novartis and AstraZeneca outside the submitted work, and has received other fees from several other pharmaceutical companies and research organisations in connection with the costs of running a broad research portfolio, outside the submitted work. ADC and AMO declare no competing interests.

PY - 2015

Y1 - 2015

UR - https://www.scopus.com/pages/publications/84953742060

U2 - 10.1016/S1470-2045(15)00311-3

DO - 10.1016/S1470-2045(15)00311-3

M3 - Letter

C2 - 26433820

AN - SCOPUS:84953742060

SN - 1470-2045

VL - 16

SP - e478-e479

JO - The Lancet Oncology

JF - The Lancet Oncology

IS - 13

ER -